ORGONasdaqPharmaceutical PreparationsUS GAAP · USD

Organogenesis Holdings Inc.

Organogenesis Holdings Inc. develops, manufactures, and sells regenerative medicine products for advanced wound care and for surgical and sports medicine uses. Its portfolio includes tissue-based and cell-based products used by hospitals, wound care centers, ambulatory surgery centers, physician offices, and government facilities, with most sales generated in the United States and additional commercial activity in select international markets.

Kysy yhtiöstä
Liikevaihto564milj. USD
+17,0 %v/v
Liikevoitto (EBIT)44,7milj. USD
+3 583,6 %v/v
EBIT-marginaali7,9%
+8,2 %-yks.v/v
Nettotulos37,0milj. USD
+4 201,0 %v/v
Vapaa kassavirta−24,5milj. USD
−685,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−2000200400600milj. USD2020: 338 milj. USD2020: EBIT 27 milj. USD20202021: 467 milj. USD2021: EBIT 72 milj. USD20212022: 451 milj. USD2022: EBIT 22 milj. USD20222023: 433 milj. USD2023: EBIT 13 milj. USD20232024: 482 milj. USD2024: EBIT −1,3 milj. USD20242025: 564 milj. USD2025: EBIT 45 milj. USD202556445
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Organogenesis Holdings Inc.

Liiketoiminta

Osuus liikevaihdosta
Advanced Wound Care70 %

Biologic and tissue-based products used to support healing of chronic and complex wounds.

Surgical & Sports Medicine25 %

Products used in surgical procedures and orthopedic or sports medicine applications.

International Distribution5 %

Commercial sales of selected products in markets outside the United States.

Tuotteet

Raportoitu · osuus liikevaihdosta
99,8%FY2025100 %
  • Products99,8 %
  • Grant0,2 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Organogenesis sells primarily to healthcare providers that treat chronic wounds or perform procedures requiring regenerative tissue products. Its customer base includes hospitals, wound care centers, government facilities, ambulatory surgery centers, and physician offices, with purchasing driven by clinical use, reimbursement, and product availability.

Hospitals

Buy advanced wound care and surgical products for procedure-based healing and inpatient/outpatient use.

Wound care centers

Purchase skin substitutes and biologics for chronic wound treatment protocols.

Ambulatory surgery centers

Use surgical and sports medicine tissue products in outpatient procedures.

Physician offices

Buy products for office-based wound management and follow-up care.

Government facilities

Purchase through public healthcare channels where reimbursement and coverage rules matter.

Strategia

Organogenesis focuses on expanding clinical evidence for its products, because outcomes data supports physician adoption and reimbursement positioning. It also invests in direct sales coverage, manufacturing capability, and selective international commercialization while maintaining a portfolio across wound care and surgical applications.

Generate clinical and real-world outcomes dataKeskipitkä aikaväli

Evidence supports physician confidence, payer coverage, and product differentiation.

Strengthen U.S. commercial executionLyhyt aikaväli

The company relies on direct sales relationships and field coverage to drive utilization.

Expand manufacturing and operating infrastructureKeskipitkä aikaväli

Production capacity and facility readiness support growth and product availability.

Broaden geographic reach selectivelyPitkä aikaväli

International registrations can extend the product portfolio beyond the U.S. market.

Maantiede

The company is primarily a U.S. business, and its direct sales force in the United States represents the core of revenue generation. It also sells selected products in Switzerland and through distributors or agents in Saudi Arabia, Kuwait, and Mexico, with additional international expansion opportunities under evaluation, including the European Union.

Riskit

The business is exposed to reimbursement decisions, especially Medicare coverage and payment policy for skin substitute products, because customer demand depends on payer support. It also faces intense competition, regulatory requirements, and execution risk in manufacturing, sales coverage, and information systems, all of which can affect product adoption and operating performance.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Medicare coverage and reimbursement changes1Proposed non-coverage LCDs for certain products2Regulatory and quality compliance3Intense competition and product substitution4IT and information security disruptions5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Medicare coverage and reimbursement changesVaikutus: KorkeaTodennäköisyys: Korkea

    Demand for wound care products depends heavily on payer payment policy and coverage decisions.

    Kohdistuu: Advanced wound care and skin substitute products

  2. Proposed non-coverage LCDs for certain productsVaikutus: KorkeaTodennäköisyys: Korkea

    If finalized, non-coverage could reduce utilization of specific products in Medicare populations.

    Kohdistuu: Skin substitute grafts/CTPs for DFUs and VLUs

  3. Regulatory and quality complianceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA and other healthcare regulations govern product approvals, manufacturing, and distribution.

    KohdistuuPMA510(k)HCT/P-regulated products
  4. Intense competition and product substitutionVaikutus: KeskitasoTodennäköisyys: Korkea

    The company competes against skin substitutes, placental-based products, and traditional wound care.

    Kohdistuu: Advanced wound care and surgical markets

  5. IT and information security disruptionsVaikutus: KeskitasoTodennäköisyys: Matala

    Operational systems support sales, manufacturing, and customer service, so outages can impair execution.

    Kohdistuu: Commercial and manufacturing infrastructure

Kysy Clarifolta: Organogenesis Holdings Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Revenue can be recorded on procedure date, shipment, or delivery depending on contract terms.

Vaikutus: Affects quarterly revenue comparability and reported growth rates

Reserves for returns, discounts, and GPO rebates

These deductions are recorded against gross sales and require estimation.

Vaikutus: Affects net revenue and margin presentation

Seasonality

Fourth-quarter hospital buying is typically stronger due to budget cycles and deductibles.

Vaikutus: Creates uneven quarterly revenue and working capital patterns

Impairment and estimate judgments

Management cites goodwill, long-lived assets, leases, and taxes as judgment-heavy areas.

Vaikutus: Can materially affect earnings and balance sheet values

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

MiMedx Group, Inc

MDXG · Surgical & Medical Instruments & Apparatus

Regenerex Pharma, Inc.

Pharmaceutical Preparations

Celularity Inc

CELU · Pharmaceutical Preparations

Oragenics Inc

OGEN · Pharmaceutical Preparations

Regenerative Medical Technology Group Inc.

RMTG · Retail-Retail Stores, NEC

Organon & Co.

OGN · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Organogenesis Holdings Inc. (ORGO) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo